Minocycline (as the hydrochloride)

Generic name
Minocycline (as the hydrochloride)
Brand name
ATC Code
J01AA08
Compare …

Minocycline (as the hydrochloride)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No pharmacokinetic studies have been carried out in children.
 

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Bacterial infections
  • Oral
    • 8 years up to 12 years
      • Initial dose: 4 mg/kg/day in 1 dose. Max: 200 mg/day.
      • Maintenance dose: 2 - 4 mg/kg/day in 1 - 2 doses. Max: 200 mg/day.
    • 12 years up to 18 years
      • Initial dose: 200 mg/day in 1 dose
      • Maintenance dose: 100 - 200 mg/day in 1 - 2 doses.
Severe acne vulgaris
  • Oral
    • 8 years up to 18 years
      • 100 mg/day in 2 doses.

      • After the inflammatory phase has been reduced, the maintenance dose can be brought back to 50 mg once a day or 100 mg every two days if the clinical effect justifies it.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Gastrointestinal disorders such as nausea, vomiting, diarrhoea, rare cases of pseudomembranous colitis and staphylococcal enteritis, negative effects on bones and teeth in children. Intracranial hypertension [Fraser 2012]. Rhabdomyolysis has been described in a case report [Kempeneers 2013].

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

Children younger than 8 years

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Treatment of children aged 8–12 years should only be considered when other options are ineffective or contraindicated. Crossover sensitivity and crossover resistance can occur between tetracyclines. Deposition in growing tooth tissue causes permanent discoloration of the teeth. 

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

TETRACYCLINES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Tetracyclines
J01AA02
J01AA07
J01AA12

References

  1. Merck BV, SPC Aknemin, RVG 18030, (Geraadpleegd 14 jan 10), www.cbg-meb.nl, http://db.cbg-meb.nl/IB-teksten/h18030-h18031.pdf
  2. Mylan, SPC Minocycline (RVG 22153), www.cbg-meb.nl, http://db.cbg-meb.nl/IB-teksten/h22153.pdf
  3. Fraser CL et al. , Minocycline-induced fulminant intracranial hypertension. , Arch Neurol. , 2012 , Aug;69(8):, 1067-70
  4. Garner SE et al., Minocycline for acne vulgaris: efficacy and safety., Cochrane Database Syst Rev., 2012, Aug 15;(8):, CD002086
  5. Kempeneers D et al., Rabdomyolyse op zowel isotretinoïne als minocycline in de behandeling van acne vulgaris bij een 15-jarige jongen, Ned Tijdschr. Derm. Venereol., 2013, Mei; 23(5), 275-277
  6. Dermapharm, SmPC Udima 50 mg Kps. (1-20149), https://www.univadis.at/, 05/2018
  7. Aurobindo, SmPC Minocycline (RVG 22098) 09-11-2018, www.geneesmiddelinformatiebank.nl
  8. Fraser CL et al., Minocycline-induced fulminant intracranial hypertension., Arch Neurol., 2012, Aug;69(8):, 1067-70

Changes

Therapeutic Drug Monitoring


Overdose